Risk of depression after diagnostic prostate cancer workup – A nationwide, registry-based study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Risk of depression after diagnostic prostate cancer workup – A nationwide, registry-based study. / Friberg, Anne Sofie; Brasso, Klaus; Larsen, Signe Benzon; Andersen, Elisabeth Wreford; Krøyer, Anja; Helgstrand, John Thomas; Røder, Martin Andreas; Klemann, Nina; Kessing, Lars Vedel; Johansen, Christoffer; Dalton, Susanne Oksbjerg.

In: Psycho-Oncology, Vol. 30, No. 11, 2021, p. 1939-1947.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Friberg, AS, Brasso, K, Larsen, SB, Andersen, EW, Krøyer, A, Helgstrand, JT, Røder, MA, Klemann, N, Kessing, LV, Johansen, C & Dalton, SO 2021, 'Risk of depression after diagnostic prostate cancer workup – A nationwide, registry-based study', Psycho-Oncology, vol. 30, no. 11, pp. 1939-1947. https://doi.org/10.1002/pon.5766

APA

Friberg, A. S., Brasso, K., Larsen, S. B., Andersen, E. W., Krøyer, A., Helgstrand, J. T., Røder, M. A., Klemann, N., Kessing, L. V., Johansen, C., & Dalton, S. O. (2021). Risk of depression after diagnostic prostate cancer workup – A nationwide, registry-based study. Psycho-Oncology, 30(11), 1939-1947. https://doi.org/10.1002/pon.5766

Vancouver

Friberg AS, Brasso K, Larsen SB, Andersen EW, Krøyer A, Helgstrand JT et al. Risk of depression after diagnostic prostate cancer workup – A nationwide, registry-based study. Psycho-Oncology. 2021;30(11):1939-1947. https://doi.org/10.1002/pon.5766

Author

Friberg, Anne Sofie ; Brasso, Klaus ; Larsen, Signe Benzon ; Andersen, Elisabeth Wreford ; Krøyer, Anja ; Helgstrand, John Thomas ; Røder, Martin Andreas ; Klemann, Nina ; Kessing, Lars Vedel ; Johansen, Christoffer ; Dalton, Susanne Oksbjerg. / Risk of depression after diagnostic prostate cancer workup – A nationwide, registry-based study. In: Psycho-Oncology. 2021 ; Vol. 30, No. 11. pp. 1939-1947.

Bibtex

@article{dd2d24416a6748fb991d41ebadeb674b,
title = "Risk of depression after diagnostic prostate cancer workup – A nationwide, registry-based study",
abstract = "Objective: To compare the risk of depression after diagnostic workup for prostate cancer (PCa), regardless of the histopathologic outcome, with that of a cancer-free population. Methods: A nationwide cohort of Danish men who had a prostatic biopsy sample in 1998–2011 was identified from the Danish Prostate Cancer Registry and compared to an age-matched cohort from the background population. Men with other cancers, major psychiatric disorder, or prior use of antidepressants were excluded. The risk of depression defined as hospital contact for depression or prescription for antidepressants was determined from cumulative incidence functions and multivariate Cox regression models. Results: Of 54,766 men who underwent diagnostic workup for PCa, benign results were found for 21,418 and PCa was diagnosed in 33,347. During up to 18 years of follow-up, the adjusted hazard of depression was higher in men with PCa than in the background population, with the highest risk in the two years after diagnosis (hazard ratio (HR) 2.77, 95% CI 2.66–2.87). Comorbidity and lowest or highest income were significant risk factors for depression and the cumulative incidence was substantially higher in men with metastatic or high-risk disease. In men with benign histopathology the HR for depression was 1.22 (95% CI 1.14–1.31) in the first two years but no different from the background population after that. Conclusions: Diagnostic workup for PCa is associated with an increased risk of depression, mainly among men with a diagnosis of PCa. Clinicians should be aware of depressive symptoms in prostate cancer patients.",
keywords = "antidepressant drugs, cancer, cancer survivors, depression, oncology, prostate cancer, psycho-oncology, severe mental disorders, survivorship, transrectal high intensity focused ultrasound",
author = "Friberg, {Anne Sofie} and Klaus Brasso and Larsen, {Signe Benzon} and Andersen, {Elisabeth Wreford} and Anja Kr{\o}yer and Helgstrand, {John Thomas} and R{\o}der, {Martin Andreas} and Nina Klemann and Kessing, {Lars Vedel} and Christoffer Johansen and Dalton, {Susanne Oksbjerg}",
note = "Publisher Copyright: {\textcopyright} 2021 John Wiley & Sons Ltd.",
year = "2021",
doi = "10.1002/pon.5766",
language = "English",
volume = "30",
pages = "1939--1947",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "JohnWiley & Sons Ltd",
number = "11",

}

RIS

TY - JOUR

T1 - Risk of depression after diagnostic prostate cancer workup – A nationwide, registry-based study

AU - Friberg, Anne Sofie

AU - Brasso, Klaus

AU - Larsen, Signe Benzon

AU - Andersen, Elisabeth Wreford

AU - Krøyer, Anja

AU - Helgstrand, John Thomas

AU - Røder, Martin Andreas

AU - Klemann, Nina

AU - Kessing, Lars Vedel

AU - Johansen, Christoffer

AU - Dalton, Susanne Oksbjerg

N1 - Publisher Copyright: © 2021 John Wiley & Sons Ltd.

PY - 2021

Y1 - 2021

N2 - Objective: To compare the risk of depression after diagnostic workup for prostate cancer (PCa), regardless of the histopathologic outcome, with that of a cancer-free population. Methods: A nationwide cohort of Danish men who had a prostatic biopsy sample in 1998–2011 was identified from the Danish Prostate Cancer Registry and compared to an age-matched cohort from the background population. Men with other cancers, major psychiatric disorder, or prior use of antidepressants were excluded. The risk of depression defined as hospital contact for depression or prescription for antidepressants was determined from cumulative incidence functions and multivariate Cox regression models. Results: Of 54,766 men who underwent diagnostic workup for PCa, benign results were found for 21,418 and PCa was diagnosed in 33,347. During up to 18 years of follow-up, the adjusted hazard of depression was higher in men with PCa than in the background population, with the highest risk in the two years after diagnosis (hazard ratio (HR) 2.77, 95% CI 2.66–2.87). Comorbidity and lowest or highest income were significant risk factors for depression and the cumulative incidence was substantially higher in men with metastatic or high-risk disease. In men with benign histopathology the HR for depression was 1.22 (95% CI 1.14–1.31) in the first two years but no different from the background population after that. Conclusions: Diagnostic workup for PCa is associated with an increased risk of depression, mainly among men with a diagnosis of PCa. Clinicians should be aware of depressive symptoms in prostate cancer patients.

AB - Objective: To compare the risk of depression after diagnostic workup for prostate cancer (PCa), regardless of the histopathologic outcome, with that of a cancer-free population. Methods: A nationwide cohort of Danish men who had a prostatic biopsy sample in 1998–2011 was identified from the Danish Prostate Cancer Registry and compared to an age-matched cohort from the background population. Men with other cancers, major psychiatric disorder, or prior use of antidepressants were excluded. The risk of depression defined as hospital contact for depression or prescription for antidepressants was determined from cumulative incidence functions and multivariate Cox regression models. Results: Of 54,766 men who underwent diagnostic workup for PCa, benign results were found for 21,418 and PCa was diagnosed in 33,347. During up to 18 years of follow-up, the adjusted hazard of depression was higher in men with PCa than in the background population, with the highest risk in the two years after diagnosis (hazard ratio (HR) 2.77, 95% CI 2.66–2.87). Comorbidity and lowest or highest income were significant risk factors for depression and the cumulative incidence was substantially higher in men with metastatic or high-risk disease. In men with benign histopathology the HR for depression was 1.22 (95% CI 1.14–1.31) in the first two years but no different from the background population after that. Conclusions: Diagnostic workup for PCa is associated with an increased risk of depression, mainly among men with a diagnosis of PCa. Clinicians should be aware of depressive symptoms in prostate cancer patients.

KW - antidepressant drugs

KW - cancer

KW - cancer survivors

KW - depression

KW - oncology

KW - prostate cancer

KW - psycho-oncology

KW - severe mental disorders

KW - survivorship

KW - transrectal high intensity focused ultrasound

U2 - 10.1002/pon.5766

DO - 10.1002/pon.5766

M3 - Journal article

C2 - 34260790

AN - SCOPUS:85110742960

VL - 30

SP - 1939

EP - 1947

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

IS - 11

ER -

ID: 275774242